QUOTE AND NEWS
newratings.com  14 min ago  Comment 
BASEL (dpa-AFX) - Novartis (NVS) announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar (dabrafenib)...
newratings.com  7 hrs ago  Comment 
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma Novartis International AG / Novartis combination therapy Tafinlar® + Mekinist® demonstrates...
newratings.com  10 hrs ago  Comment 
BASEL (dpa-AFX) - Novartis (NVS) announced new data for multiple investigational and established non-small cell lung cancer or NSCLC treatments, including results from a pivotal, Phase II study of Tafinlar (dabrafenib) in combination with Mekinist...
newratings.com  10 hrs ago  Comment 
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer Novartis International AG / Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent...
Reuters  11 hrs ago  Comment 
A Novartis trial of two drugs against an aggressive lung cancer bodes well for broadening their use beyond melanoma, the Swiss drugmaker told the American Society of Clinical...
MedPage Today  Jun 6  Comment 
(MedPage Today) -- Study suggests that 10 years is better than five
Reuters  Jun 5  Comment 
Mereo BioPharma Group, a British company trialing three drugs developed by Novartis , said it would list on London's junior AIM market to raise capital to develop its drugs and...
MedPage Today  Jun 5  Comment 
(MedPage Today) -- Video discusses study showing AI benefit to 10 years
newratings.com  Jun 4  Comment 
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna® Novartis International AG / Novartis data show more than 50 percent of eligible Ph+ CML patients maintain...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki